



University of Colorado **Anschutz Medical Campus**

Voice of the Participant

NICHD, September 2025

Participant: Grace Hamilton


Primary Investigator: Melanie G Cree, MD, PhD

**Role of Semaglutide in Restoring Ovulation in Youth and Adults with Polycystic Ovary Syndrome
(RESTORE) NIH NICHD R01HD108340, NCT05819853**

Melanie.Cree@cuanschutz.edu




Polycystic Ovary Syndrome




PCOS affects 6-15% of women in the United States



PCOS and Weight




Initial Treatment Options




Little change in > 30 years

Practical Treatment Options for PCOS



PCOS and Weight Loss Medications



Losing 5 % of body weight

Weight Loss Medication (GLP1-RA)

±Metformin

Testosterone —

Insulin

Infertility

Excess hair growth on face and body
Acne
Depression/Anxiety

Excess Weight

Type 2 Diabetes
High blood pressure
High Cholesterol



Started enrolling November 2023, All controls and 5 metformin enrolled to date



PCOS+Semaglutide Trial Early Findings

10 months of weekly injections of semaglutide

First 8 participants to lose > 10 % weight



6 – more menses

1 – same menses 1 – less menses




Experience as a RESTORE participant



University of Colorado
Anschutz Medical Campus

Grace Hamilton

GLP1RA +/- Metformin to Improve Reproduction



Started enrolling November 2023, All controls and 5 metformin enrolled to date

